JP5060306B2 - カンホスファミドおよびその塩の製造方法および製造中間体、中間体を含む医薬組成物ならびに抗ガン剤としてのその使用 - Google Patents

カンホスファミドおよびその塩の製造方法および製造中間体、中間体を含む医薬組成物ならびに抗ガン剤としてのその使用 Download PDF

Info

Publication number
JP5060306B2
JP5060306B2 JP2007548240A JP2007548240A JP5060306B2 JP 5060306 B2 JP5060306 B2 JP 5060306B2 JP 2007548240 A JP2007548240 A JP 2007548240A JP 2007548240 A JP2007548240 A JP 2007548240A JP 5060306 B2 JP5060306 B2 JP 5060306B2
Authority
JP
Japan
Prior art keywords
compound
acid
benzyloxycarbonyl
phenylglycine
glutamyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007548240A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008524327A5 (enExample
JP2008524327A (ja
Inventor
ウィリアム・エイ・ブーランジャー
スティーブン・ジェイ・コリアー
スティーブン・エイ・イースタム
デニス・エル・エディー
ロナン・イグレク・ゲヴェル
ペドロ・イー・ヘルナンデス・アバド
アール・ジェイソン・ハー
ハンス・ヨズ・ケールスゴー
ハロルド・メックラー
ロバート・イー・ポロムスキー
スティーブン・アール・ショウ
ペイベル・イー・ジックキン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terrapin Technologies Inc
Original Assignee
Terrapin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terrapin Technologies Inc filed Critical Terrapin Technologies Inc
Publication of JP2008524327A publication Critical patent/JP2008524327A/ja
Publication of JP2008524327A5 publication Critical patent/JP2008524327A5/ja
Application granted granted Critical
Publication of JP5060306B2 publication Critical patent/JP5060306B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/36—Amides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2408—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyalkyl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/26—Amides of acids of phosphorus containing P-halide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44—Amides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2007548240A 2004-12-21 2005-11-23 カンホスファミドおよびその塩の製造方法および製造中間体、中間体を含む医薬組成物ならびに抗ガン剤としてのその使用 Expired - Fee Related JP5060306B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/018,391 2004-12-21
US11/018,391 US8198247B2 (en) 2004-12-21 2004-12-21 Process for and intermediates in the preparation of canfosfamide and its salts
PCT/US2005/042693 WO2006068769A1 (en) 2004-12-21 2005-11-23 Process for and intermediates in the preparation of canfosfamide and its salts, pharmaceutical compositions containing some intermediates, and their use as anticancer agents

Publications (3)

Publication Number Publication Date
JP2008524327A JP2008524327A (ja) 2008-07-10
JP2008524327A5 JP2008524327A5 (enExample) 2008-12-18
JP5060306B2 true JP5060306B2 (ja) 2012-10-31

Family

ID=36216909

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007548240A Expired - Fee Related JP5060306B2 (ja) 2004-12-21 2005-11-23 カンホスファミドおよびその塩の製造方法および製造中間体、中間体を含む医薬組成物ならびに抗ガン剤としてのその使用

Country Status (15)

Country Link
US (2) US8198247B2 (enExample)
EP (1) EP1827605B1 (enExample)
JP (1) JP5060306B2 (enExample)
KR (1) KR20070089795A (enExample)
CN (1) CN101080251B (enExample)
AR (1) AR052167A1 (enExample)
AU (1) AU2005319579B2 (enExample)
BR (1) BRPI0519141A2 (enExample)
CA (1) CA2587088A1 (enExample)
EA (1) EA016052B1 (enExample)
IL (1) IL182835A0 (enExample)
MX (1) MX2007007215A (enExample)
TW (1) TW200633717A (enExample)
WO (1) WO2006068769A1 (enExample)
ZA (1) ZA200704318B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056825A1 (en) * 2008-08-28 2010-03-04 Telik, Inc. Formulations of canfosfamide and their preparation
US8324426B2 (en) 2008-08-28 2012-12-04 Telik, Inc. Formulations of canfosfamide and their preparation
CA2733732A1 (en) * 2011-02-25 2012-08-25 Telik, Inc. Formulations of canfosfamide and their preparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556942A (en) 1991-04-29 1996-09-17 Terrapin Technologies, Inc. Glutathione S-transferase-activated compounds
EP1072608B1 (en) * 1998-04-16 2005-06-15 Teijin Limited Glutathione derivatives and dosage forms thereof
US6417397B1 (en) * 1999-10-04 2002-07-09 The Regents Of The University Of California, San Diego N-substituted alkylamino acids for use as amino-protecting groups
UA74574C2 (en) 2000-05-02 2006-01-16 Telik Inc Bis (n,n'-bis(2-halogenethyl)amino)phosphodiamates, a method for producing thereof (variants), a pharmaceutical composition containing them, and a method for the treatment of tumors
US6506739B1 (en) 2001-05-01 2003-01-14 Telik, Inc. Bis-(N,N'-bis-(2-haloethyl)amino)phosphoramidates as antitumor agents
WO2006074249A1 (en) * 2005-01-06 2006-07-13 Telik, Inc. Tripeptide and tetrapeptide thioethers

Also Published As

Publication number Publication date
AR052167A1 (es) 2007-03-07
ZA200704318B (en) 2008-09-25
KR20070089795A (ko) 2007-09-03
CN101080251A (zh) 2007-11-28
WO2006068769A1 (en) 2006-06-29
EA200701180A1 (ru) 2008-04-28
AU2005319579A1 (en) 2006-06-29
US20060135409A1 (en) 2006-06-22
AU2005319579B2 (en) 2011-07-21
US8198247B2 (en) 2012-06-12
EP1827605B1 (en) 2014-03-26
US20120238772A1 (en) 2012-09-20
CN101080251B (zh) 2012-08-29
EP1827605A1 (en) 2007-09-05
CA2587088A1 (en) 2006-06-29
BRPI0519141A2 (pt) 2008-12-30
US8334266B2 (en) 2012-12-18
TW200633717A (en) 2006-10-01
JP2008524327A (ja) 2008-07-10
IL182835A0 (en) 2007-08-19
EA016052B1 (ru) 2012-01-30
MX2007007215A (es) 2007-08-14

Similar Documents

Publication Publication Date Title
TWI759301B (zh) 聚乙二醇化卡非佐米化合物
EP3267984B1 (en) 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
JP4942653B2 (ja) スルホニルエチルホスホロジアミデート
CN105813640A (zh) 作为免疫调节剂的环肽类化合物
EP2673281B1 (en) Boron containing polybasic bacterial efflux pump inhibitors and therapeutics uses thereof
CZ412898A3 (cs) Substituované cyklopentanové sloučeniny, použitelné jako inhibitory neuraminidázy
US20090075945A1 (en) Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents
HUT61027A (en) Process for producing diphosphonic acids having antitumorous effect and pharmaceutical compositions comprising such compounds
US8334266B2 (en) Process for and intermediates in the preparation of canfosfamide and its salts
CN111417620A (zh) 肌酸前药、其组合物以及使用方法
TW200835505A (en) 2-{[2-(substituted amion)ethyl]sulfonyl}ethyl N, N, N', N'-tetrakis(2-chloroethyl)phosphorodiamidates
WO2010109008A1 (en) Prodrugs of substituted 3-(4-hydroxyphenyl)-indolin-2-ones
US20080125397A1 (en) 2 (SULFONYL)ETHYL N,N,N',N' tetrakis(2 chloroethyl)phosphorodia
ZA200609498B (en) Sulfonylethyl phosphorodiamidates for use in the treatment of cancer
JP2010511040A (ja) ２−｛［２−（置換アミノ）エチル］スルホニル｝エチルｎ，ｎ，ｎ’，ｎ’−テトラキス（２−クロロエチル）ホスホロジアミデート
KR20090087033A (ko) 2-｛［2-（치환 아미노）에틸］술포닐｝에틸 ｎ, ｎ, ｎ′,ｎ′-테트라키스（2-클로로에틸）포스포로디아미데이트
HK1102562A (en) Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents
NZ615880B2 (en) Prodrugs of d-isoglutamyl-[d/l]-tryptophan
NZ615880A (en) Prodrugs of d-isoglutamyl-[d/l]-tryptophan
WO2008066515A1 (en) 2-({2-oxo-2-[(pyridin-3-ylmethyl)amino]ethyl}sulfonyl)ethyl n,n,n',n'-tetrakis(2-chloroethyl)phosphorodiamidate
WO2012059568A1 (fr) Nouvelles molecules indolobenzazepiniques hydrosolubles demontrant des activites antimitotiques, antivasculaires et antitumorales in vivo

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081028

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111115

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20111118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120731

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120803

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150810

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees